CADILAHC.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally...

Stats
本日の出来高	856 777
平均出来高	2.11M
時価総額	0.00
EPS	INR4.77 ( 2021-12-30 )
Last Dividend	INR3.50 ( 2021-07-29 )
Next Dividend	INR0 ( N/A )
P/E	7.43
ATR14	INR0 (0.00%)

Zydus Lifesciences 相関

10 最も正の相関
BCG.NS	0.954
TIDEWATER.NS	0.948
TATVA.NS	0.941
SINTEX.NS	0.933
CLNINDIA.NS	0.932
BUTTERFLY.NS	0.932
INDLMETER.NS	0.93
GILLETTE.NS	0.929
DBL.NS	0.927
AMBICAAGAR.NS	0.925

10 最も負の相関
MUKANDENGG.NS	-0.954
JBMA.NS	-0.945
KIRLOSIND.NS	-0.939
GFSTEELS.NS	-0.937
FINCABLES.NS	-0.92
FOCUS.NS	-0.919
KEERTI.NS	-0.917
STAMPEDE.NS	-0.914
JSLHISAR.NS	-0.914
LINDEINDIA.NS	-0.913

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Zydus Lifesciences 財務諸表

Annual	2022
収益:	INR170.51B
総利益:	INR68.01B (39.89 %)
EPS:	INR19.30

FY	2022
収益:	INR170.51B
総利益:	INR68.01B (39.89 %)
EPS:	INR19.30

FY	2021
収益:	INR148.22B
総利益:	INR93.42B (63.03 %)
EPS:	INR20.84

FY	2020
収益:	INR138.12B
総利益:	INR86.63B (62.72 %)
EPS:	INR11.49

Financial Reports:

No articles found.

Zydus Lifesciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Zydus Lifesciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.12 - low (37.09%) | Divividend Growth Potential Score: 3.01 - No dividend growth expected in the near future

Information

First Dividend	INR0.200	2000-05-02
Last Dividend	INR3.50	2021-07-29
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR96.45	--
Avg. Dividend % Per Year	0.19%	--
Score	1.87	--
Div. Sustainability Score	4.12
Div.Growth Potential Score	3.01
Div. Directional Score	3.57	--

Next Divdend (Est)
(2024-07-09)

INR0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.87

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.50	0.90%
2019	INR3.50	1.00%
2020	INR3.50	1.38%
2021	INR3.50	0.73%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNTV.NS	Dividend Knight	2023-08-22	Quarterly	19	1.94%
NAVNETEDUL.NS	Dividend Junior	2023-08-07	Annually	22	1.10%
HPIL.NS	Dividend Junior	2023-09-29	Annually	5	0.89%
CARERATING.NS	Dividend Knight	2023-07-06	Semi-Annually	12	1.81%
ROSSELLIND.NS	No Dividend Player	2023-07-20	Sporadic	12	0.12%
LFIC.NS	Dividend Junior	2023-08-01	Annually	15	1.73%
GAEL.NS	Dividend Junior	2023-08-25	Annually	23	0.27%
APOLLOPIPE.NS	Dividend Junior	2023-09-15	Annually	3	0.07%
TCPLPACK.NS	Dividend Junior	2023-07-27	Annually	7	1.08%
OFSS.NS	Dividend Knight	2023-05-09	Annually	23	4.19%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.156	1.500	6.87	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.328	1.500	7.46	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	57.27	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	14.57	2.00	5.14	10.00	[0 - 30]
freeCashFlowPerShareTTM	14.57	2.00	2.71	5.43	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.470	1.000	5.49	5.49	[0.2 - 0.8]
operatingProfitMarginTTM	0.224	1.000	7.53	7.53	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.78	1.000	8.91	0	[1 - 100]
returnOnEquityTTM	0.328	2.50	8.37	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	14.57	2.00	5.14	5.43	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	14.57	2.00	5.14	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.324	1.500	-5.49	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0775	1.000	-0.562	0	[0.1 - 0.5]
Total Score				3.01

Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.